Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Viatris Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $38.86, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while ProShares UltraPro Short QQQ ETF pays none, and Viatris Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| SQQQ | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $17.86 |
52-Week Low | $36.04 | $9.49 |
Market Cap | — | $19.09B |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are predominantly bearish, with moving averages signaling sell and oscillators neutral. The ETF is designed to gain when the Nasdaq-100 declines, but its structure leads to value erosion over time due to daily resets. Recent news highlights its use as a tactical hedge amid tech sector volatility but warns of long-term unsuitability.
The outlook for SQQQ is highly speculative and short-term oriented. It may offer tactical gains if tech stocks weaken, but structural decay and high volatility pose significant risks. Investors should view it as a hedging tool rather than a long-term holding, with success dependent on precise market timing and active management.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
